Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Solaymani-Dodaran
  IRCT20200318046812N1		 RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
193/187 inconclusive
    ELACOI (Lopinavir/ritonavir)
          NCT04252885    		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
    		35/34 inconclusive
    • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    GS-US-540-5773 (Goldman)
          NCT04292899    		 RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
    		200/197 suggested
    • suggested 53 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
    Hung et al.
          NCT04276688    		 RCTlopinavir/ritonavir, ribavirin and interferon beta-1blopinavir/ritonavirCOVID-19 mild to moderatesome concern
    		86/41 conclusif
    • demonstrated 3.4-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 2.9-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    Ren
          ChiCTR2000029853    		 RCTazvudineantiviral and associated therapyCOVID-19 mild to moderatesome concern
    		10/10 suggested
    • suggested 27.5-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    1 study excluded by filtering options (1 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons